F1000Res. 2014 Oct 21;3:248. doi: 10.12688/f1000research.4709.1. eCollection 2014.

Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis.

F1000Research

April W Armstrong, Julie Wu, Mary Ann Johnson, Dmitry Grapov, Baktazh Azizi, Jaskaran Dhillon, Oliver Fiehn

PMID: 25580230 PMCID: PMC4288418 DOI: 10.12688/f1000research.4709.1

Abstract

IMPORTANCE: While "omics" studies have advanced our understanding of inflammatory skin diseases, metabolomics is mostly an unexplored field in dermatology.

OBJECTIVE: We sought to elucidate the pathogenesis of psoriatic diseases by determining the differences in metabolomic profiles among psoriasis patients with or without psoriatic arthritis and healthy controls.

DESIGN: We employed a global metabolomics approach to compare circulating metabolites from patients with psoriasis, psoriasis and psoriatic arthritis, and healthy controls.

SETTING: Study participants were recruited from the general community and from the Psoriasis Clinic at the University of California Davis in United States.

PARTICIPANTS: We examined metabolomic profiles using blood serum samples from 30 patients age and gender matched into three groups: 10 patients with psoriasis, 10 patients with psoriasis and psoriatic arthritis and 10 control participants. Main outcome(s) and measures(s): Metabolite levels were measured calculating the mean peak intensities from gas chromatography time-of-flight mass spectrometry.

RESULTS: Multivariate analyses of metabolomics profiles revealed altered serum metabolites among the study population. Compared to control patients, psoriasis patients had a higher level of alpha ketoglutaric acid (Pso: 288 ± 88;

CONTROL: 209 ± 69; p=0.03), a lower level of asparagine (Pso: 5460 ± 980;

CONTROL: 7260 ± 2100; p=0.02), and a lower level of glutamine (Pso: 86000 ± 20000;

CONTROL: 111000 ± 27000; p=0.02). Compared to control patients, patients with psoriasis and psoriatic arthritis had increased levels of glucuronic acid (Pso + PsA: 638 ± 250;

CONTROL: 347 ± 61; p=0.001). Compared to patients with psoriasis alone, patients with both psoriasis and psoriatic arthritis had a decreased level of alpha ketoglutaric acid (Pso + PsA: 186 ± 80; Pso: 288 ± 88; p=0.02) and an increased level of lignoceric acid (Pso + PsA: 442 ± 280; Pso: 214 ± 64; p=0.02).

CONCLUSIONS AND RELEVANCE: The metabolite differences help elucidate the pathogenesis of psoriasis and psoriatic arthritis and they may provide insights for therapeutic development.

References

1. Arch Dermatol Res. 1995;287(2):171-5 - PubMed
2. Arthritis Rheum. 2013 May;65(5):1160-70 - PubMed
3. Trends Analyt Chem. 2008 Mar;27(3):261-269 - PubMed
4. Wound Repair Regen. 1999 Mar-Apr;7(2):79-89 - PubMed
5. J Am Acad Dermatol. 2013 Nov;69(5):729-735 - PubMed
6. J Cell Physiol. 1990 Apr;143(1):94-9 - PubMed
7. Clin Chim Acta. 1982 Dec 9;126(2):119-26 - PubMed
8. Int J Rheum Dis. 2013 Dec;16(6):667-73 - PubMed
9. J Pathol. 1999 Feb;187(3):358-64 - PubMed
10. F1000Res. 2014 Oct 21;3:248 - PubMed
11. Int J Biochem Cell Biol. 2000 Mar;32(3):269-88 - PubMed
12. Cell Biochem Funct. 2004 Sep-Oct;22(5):321-6 - PubMed
13. Nat Genet. 2009 Feb;41(2):199-204 - PubMed
14. N Engl J Med. 2009 Jul 30;361(5):496-509 - PubMed
15. Bioinformatics. 2008 Aug 1;24(15):1733-4 - PubMed
16. Nature. 1988 Mar 24;332(6162):376-8 - PubMed
17. BMC Genomics. 2013 Nov 23;14:825 - PubMed
18. Biol Pharm Bull. 2007 Aug;30(8):1395-9 - PubMed
19. IUBMB Life. 2002 Oct;54(4):177-86 - PubMed
20. G Ital Dermatol Venereol. 2013 Oct;148(5):501-4 - PubMed
21. Ageing Res Rev. 2003 Jul;2(3):263-85 - PubMed
22. J Cell Physiol. 1989 Feb;138(2):221-6 - PubMed
23. Indian J Clin Biochem. 2010 Oct;25(4):388-92 - PubMed
24. Arch Dermatol Res. 2012 Aug;304(6):475-9 - PubMed
25. Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14 - PubMed
26. Arthritis Res Ther. 2013 Aug 22;15(4):R94 - PubMed
27. J Invest Dermatol. 2004 Mar;122(3):707-16 - PubMed
28. Ann Rheum Dis. 1985 Feb;44(2):83-8 - PubMed
29. Amino Acids. 2012 Jun;42(6):2491-500 - PubMed
30. Acta Biomater. 2014 Apr;10(4):1558-70 - PubMed
31. J Invest Dermatol. 1975 Sep;65(3):315-9 - PubMed
32. Br J Dermatol. 1995 May;132(5):710-7 - PubMed
33. J Biol Chem. 1989 Feb 5;264(4):2272-8 - PubMed
34. J Cell Biol. 1994 Mar;124(5):817-25 - PubMed
35. J Invest Dermatol. 1992 Jul;99(1):27-34 - PubMed
36. Nat Genet. 2010 Nov;42(11):985-90 - PubMed
37. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7 - PubMed
38. Diabetes. 1997 Jan;46(1):3-10 - PubMed
39. ISRN Dermatol. 2013 May 30;2013:630620 - PubMed
40. BMC Bioinformatics. 2012 May 16;13:99 - PubMed
41. Scand J Clin Lab Invest. 1983 May;43(3):223-5 - PubMed
42. Pac Symp Biocomput. 2007;:169-80 - PubMed
43. Int J Rheum Dis. 2011 Oct;14(4):313-9 - PubMed
44. Br J Dermatol. 1983 Aug;109(2):157-64 - PubMed
45. Int J Mol Med. 2011 Nov;28(5):785-92 - PubMed
46. J Invest Dermatol. 2010 Jul;130(7):1785-96 - PubMed
47. J Leukoc Biol. 2000 Jun;67(6):834-40 - PubMed
48. J Proteome Res. 2010 Jun 4;9(6):3062-72 - PubMed
49. Arch Dermatol Res. 1988;280(2):77-82 - PubMed
50. Plant Mol Biol. 2002 Jan;48(1-2):155-71 - PubMed
51. BMC Dermatol. 2013 Aug 14;13:8 - PubMed
52. Science. 1988 Sep 9;241(4871):1349-52 - PubMed
53. Clin Transl Sci. 2012 Jun;5(3):285-8 - PubMed
54. Diabetes Res Clin Pract. 2013 Jan;99(1):12-8 - PubMed
55. Autoimmunity. 2007 Mar;40(2):131-7 - PubMed
56. J Am Acad Dermatol. 2014 Mar;70(3):512-6 - PubMed
57. Proteomics. 2004 Jan;4(1):78-83 - PubMed
58. Ciba Found Symp. 1989;143:233-40; discussion 240-7, 281-5 - PubMed
59. Arthritis Rheum. 1991 Jul;34(7):815-21 - PubMed
60. Anal Biochem. 2007 Apr 15;363(2):185-95 - PubMed
61. J Nutr. 2001 Sep;131(9 Suppl):2539S-42S; discussion 2550S-1S - PubMed

Publication Types

• Journal Article

Grant support

• K08 HS018341/HS/AHRQ HHS/United States
• U24 DK097154/DK/NIDDK NIH HHS/United States